A recent comprehensive review highlighted the importance of ERBB2 mutations in the clinical management of NSCLC patients, and several drugs targeting ERBB2 insertion in exon 20, such as trastuzumab deruxtecan, poziotinib and pyrotinib, have been under clinical trials.6 Here, ERBB2 is linked to non-small cell lung carcinoma.